EPO protects Müller cell under high glucose state through BDNF/TrkB pathway

Area of Science:

• Ophthalmology
• Neuroscience
• Endocrinology

Background:

• Diabetic retinopathy involves decreased neurotrophic factors and neuronal damage.
• Brain-derived neurotrophic factor (BDNF) and its receptor TrkB expression are reduced in early diabetic retinal damage.
• Erythropoietin (EPO) shows potential in protecting against early diabetic retinopathy.

Purpose of the Study:

• To investigate the protective effects of EPO on diabetic retinopathy in a rat model.
• To analyze the impact of EPO on key molecular markers including BDNF, TrkB, ERK, and GFAP.
• To elucidate the potential neuroprotective pathway involving BDNF/TrkB.

Main Methods:

• Vitreous injection of EPO in diabetic rats.
• Histopathological examination using Hematoxylin and Eosin (HE) staining.
• Detection of protein expression via Immunohistochemistry, Immunofluorescence, and Western blot for BDNF, TrkB, ERK, and GFAP.

Main Results:

• EPO treatment improved retinal thickness and retinal ganglion cell (RGC) count compared to untreated diabetic rats.
• EPO administration increased BDNF and TrkB expression while decreasing GFAP and ERK levels.
• TrkB levels showed dynamic changes, increasing at 4 weeks and decreasing by 24 weeks post-injection in EPO-treated groups.

Conclusions:

• EPO vitreous injection demonstrates neuroprotective effects in diabetic rat retinas.
• EPO enhances BDNF and TrkB expression, potentially via the BDNF/TrkB pathway.
• EPO treatment mitigates Müller cell damage and supports neuronal nutrition in diabetic retinopathy.